SCHEMBL1663232

SCHEMBL1663232

CC(C)(C)OC(=O)N1CCN(c2ccc(F)c(C(=O)O)c2F)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GPR119 Q8TDV5 5/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CKS1B P61024 1/20 0.44
SKP1 P63208 1/20 0.44
SKP2 Q13309 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.42
TP53 P04637 1/20 0.42
THRB P10828 1/20 0.42
SMARCA2 P51531 1/20 0.42
SMARCA4 P51532 1/20 0.42
PBRM1 Q86U86 1/20 0.42
NPC1 O15118 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29471910 1.00 MAPT (0.46) MAPTALDH1A1LMNASMN1; SMN2GPR119
SCHEMBL20046895 0.89 SMN1; SMN2 (0.48) MAPTALDH1A1LMNASMN1; SMN2GPR119
SCHEMBL1665397 0.85 GPR119 (0.44) MAPTALDH1A1LMNASMN1; SMN2GPR119
SCHEMBL31651685 0.82 MAPT (0.46) MAPTALDH1A1LMNASMN1; SMN2GPR119
SCHEMBL1662688 0.81 GPR119 (0.48) MAPTALDH1A1LMNASMN1; SMN2GPR119
SCHEMBL12957576 0.80 TP53 (0.51) MAPTALDH1A1LMNASMN1; SMN2GPR119
SCHEMBL22532774 0.80 SMN1; SMN2 (0.56) MAPTALDH1A1LMNASMN1; SMN2GPR119
SCHEMBL21995951 0.80 MAPT (0.49) MAPTALDH1A1LMNASMN1; SMN2GPR119
SCHEMBL111206 0.80 SMN1; SMN2 (0.56) MAPTALDH1A1LMNASMN1; SMN2GPR119
SCHEMBL671742 0.80 TTR (0.53) MAPTALDH1A1LMNASMN1; SMN2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242987-B2 Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors CELLZOME LIMITED (GB) 2016-01-26 US disclosed
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2012-10-04 US disclosed
EP-2491039-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS Cellzome Limited (GB) 2012-08-29 EP disclosed
WO-2011048082-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS JAK1, JAK3, JAK2 MAPT 4393/4885ALDH1A1 2233/4885LMNA 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.